Moderna, Inc. (MRNA)

NASDAQ: MRNA · IEX Real-Time Price · USD
104.46
+3.05 (3.01%)
At close: Apr 22, 2024, 4:00 PM
104.40
-0.06 (-0.06%)
After-hours: Apr 22, 2024, 7:58 PM EDT
3.01%
Market Cap 40.00B
Revenue (ttm) 6.85B
Net Income (ttm) -4.71B
Shares Out 382.88M
EPS (ttm) -12.33
PE Ratio n/a
Forward PE 32.47
Dividend n/a
Ex-Dividend Date n/a
Volume 3,090,290
Open 102.79
Previous Close 101.41
Day's Range 99.30 - 105.43
52-Week Range 62.55 - 142.79
Beta 1.59
Analysts Hold
Price Target 132.00 (+26.36%)
Earnings Date May 2, 2024

About MRNA

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vac... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 7, 2018
Employees 5,600
Stock Exchange NASDAQ
Ticker Symbol MRNA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price forecast is $132.0, which is an increase of 26.36% from the latest price.

Price Target
$132.0
(26.36% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign

CAMBRIDGE, MA / ACCESSWIRE / April 22, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a contract with the Ministry of Health in Brazil (Ministério da Saúde) to supply its mRNA COVID-19 vaccine as ...

18 hours ago - Accesswire

Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024

CAMBRIDGE, MA / ACCESSWIRE / April 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024 to report its f...

5 days ago - Accesswire

Moderna Betrays Africa, Says AHF

LOS ANGELES--(BUSINESS WIRE)-- #Africa--AIDS Healthcare Foundation (AHF) says Moderna's promise to build a state-of-the-art mRNA manufacturing facility in Africa in 2022 was nothing more than a self-s...

11 days ago - Business Wire

Moderna halts plans to build Kenya vaccine plant as Covid shot demand plunges

Moderna's decision aligns with its broader effort to cut costs by resizing its Covid vaccine manufacturing footprint.

11 days ago - CNBC

Moderna puts Kenya plant plans on hold as COVID vaccine demand slumps

Moderna said on Thursday it had paused its plans to build a vaccine manufacturing facility in Kenya, following a post-pandemic decline in demand for COVID-19 vaccines.

11 days ago - Reuters

Among the biggest winners today are some major long-term losers, says Jim Cramer

'Mad Money' host Jim Cramer looks at today's market winners and losers.

Other symbols: NVDARCL
13 days ago - CNBC Television

Moderna Reports Positive Results from Cancer Vaccine-Keytruda Combination Trial

Moderna (MRNA) shares jumped Tuesday after the biotech firm reported positive results from a small trial involving those with head and neck cancers treated with its experimental individualized MRNA ca...

13 days ago - Investopedia

Moderna's stock jumps 6% as its cancer vaccine could treat more than just melanoma

Moderna Inc.'s stock jumped 6% Tuesday to lead S&P 500 gainers, after the company shared cancer-vaccine data that suggests it may work in indications outside its target of melanoma.

13 days ago - Market Watch

What made Moderna stock pop 10% on Tuesday?

Moderna Inc (NASDAQ: MRNA) popped as much as 10% on Tuesday after a Jefferies analyst made upbeat remarks on new data for its experimental vaccine for head and neck cancer.

13 days ago - Invezz

Moderna jumps as personalized cancer vaccine shows benefit in early study

Moderna shares rose 8% in morning trade on Tuesday after the company's individualized cancer vaccine developed with Merck showed positive response in an early-stage trial in patients with a type of he...

13 days ago - Reuters

Moderna shares fall after judge sides with Arbutus in patent fight

Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus' arguments in a patent infringement lawsuit related to Moderna's blockbuster COVID-19 vaccines.

19 days ago - Reuters

Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature

CAMBRIDGE, MA / ACCESSWIRE / April 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that interim data for a first-in-human, phase 1/2, open-label, dose optimization study and extension study, eva...

19 days ago - Accesswire

Three top U.S. biotech stocks to buy in April

“Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024.

Other symbols: NBIXVRTX
25 days ago - Invezz

Moderna CEO talks China investment, vaccine updates to boost growth post-pandemic

Moderna (MRNA) is advancing three of its vaccines into Phase Three trials as the pharmaceutical giant hopes to expand its product pipeline past its COVID-19 vaccine, sales of which fell by 43% year-ov...

26 days ago - Yahoo Finance

Moderna Gets $750 Million in Flu Shot Funding, Stock Advances

Moderna Inc. (MRNA) shares advanced Wednesday as the biotech firm used its “Vaccines Day” event to make key announcements about new funding and the results of several vaccine trials.

26 days ago - Investopedia

Moderna shares continue to fall even as its 3 vaccines enter final stage trials

Moderna Inc. saw its stock continue its downward trajectory on Wednesday morning, slipping by 1.2 percent to $106.21, following a decline of over 3 percent on Tuesday. The biotech company's shares hav...

26 days ago - Invezz

CARsgen Announced 2023 Annual Results

SHANGHAI , March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematol...

26 days ago - PRNewsWire

Moderna moves three vaccines into final stage trials as it works to rebound from Covid slump

Moderna will chart its post-Covid future Wednesday during its fifth annual "Vaccines Day," an investor event in Boston.

26 days ago - CNBC

Moderna CEO on vaccines pipeline: Investing aggressively to bring important medicine to patients

Moderna CEO Stephane Bancel joins 'Squawk Box' to discuss the company's annual vaccines day, the announcement of multiple vaccine programs advancing to late-stage clinical trials, Moderna's vaccines p...

26 days ago - CNBC Television

Moderna Gets $750 Million for Flu Program. Funding to Help Move Beyond Covid Vaccines.

The vaccine maker announces that Blackstone Life Sciences has agreed to fund up to $750 million for its flu program.

26 days ago - Barrons

Moderna gets $750 mln funding from Blackstone Life Sciences to develop flu shots

Moderna said on Wednesday it has entered into an agreement with private equity firm Blackstone's life science investment platform for a funding of $750 million to develop its mRNA flu vaccines.

Other symbols: BX
26 days ago - Reuters

Blackstone Life Sciences Announces Collaboration to Support Moderna's Influenza Program

NEW YORK--(BUSINESS WIRE)--Blackstone (NYSE:BX) announced today a new collaboration with Moderna, Inc. (NASDAQ: MRNA, “Moderna”) through a development and commercialization funding agreement where fun...

Other symbols: BX
26 days ago - Business Wire

Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpoints Expects two more Phase 3 readouts in 2024, including combination vaccine a...

26 days ago - Accesswire

Moderna Says 'Next-Generation' COVID-19 Shot Had Positive Phase 3 Test Results

Moderna Inc. (MRNA) on Tuesday reported "positive interim results" from a late-stage study of what it calls the "next-generation COVID-19 vaccine."

27 days ago - Investopedia

Moderna says new Covid vaccine showed stronger immune response than current shot in study

Moderna's new shot offers the potential of a longer shelf life and is one component of its combination vaccine targeting Covid and the flu.

27 days ago - CNBC